Orphan Drug Designation (ODD) granted to Vonafexor for Alport syndrome by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA)
ENYO Pharma announces that both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted Orphan Drug Designation (ODD) to Vonafexor, our fibrolytic & anti-inflammatory clinical compound, for the treatment of Alport syndrome.
Alport syndrome is a rare kidney disease, a genetic disorder affecting 1 in 5,000-10,000 live births. It is characterized by a progressive loss of kidney function and may result in hearing loss and eye abnormalities.
5th CKD Summit – Chronic Kidney Disease Drug Development
7-9 March, 2023
Boston, MA
ENYO was attending the 5th Chronic Kidney Disease Drug Development Summit, an industry forum sharing cross-industry insight to bring effective therapies to patients suffering from kidney diseases expanding also to rare renal disorders.
New publication: Hepatic and renal improvements with FXR agonist Vonafexor in individuals with suspected fibrotic NASH
ENYO Pharma is proud to share the publication of the results from our Phase 2 LIVIFY study with Vonafexor in NASH patients in Journal of Hepatology.
This article describes the remarkable effects of Vonafexor after only 12 weeks of treatment in these patients: strong liver fat reduction, weight loss, liver enzyme improvements …., and last but not least renal function recovery. These strongly differentiated fibrolytic and anti-inflammatory effects of Vonafexor compared to other FXR agonists correlate very well with those observed in several preclinical models of severe CKD and rare kidney diseases like Alport Syndrome.
2022 International HBV Meeting
18-22 September, 2022
Paris, France.
ENYO Pharma sponsored and attent the 2022 International HBV Meeting on 18-22 September, 2022 organized by our collaborator Dr. David Durantel, Director of Research in Infectiology and team leader at the International Center for Research in Infectiology (CIRI-INSERM), Lyon, France.
https://www.hbvmeeting.org/
ASN Kidney Week
3-6 November 2022
Orlando, FL
ENYO Pharma was attending the world’s premier nephrology meeting of the American Society of Nephrology, ASN Kidney Week
https://www.asn-online.org/education/kidneyweek/
Latest Press Release 